Estee Palm, HIV candidate for a new drug, selected as a project to be supported by the National Institute of Health

Estee Palm, HIV candidate for a new drug, selected as a project to be supported by the National Institute of Health

Last modification on the 2018.10.23 10:31Enter the article 2018.10.23 10:31

[아시아경제 박혜정 기자] STH03-0404, a new drug candidate for the treatment of human immunodeficiency virus (HIV) infection, has been selected as a project to support the National Institutes of Health research project (NIH ) in the field of life sciences.

STEP Palm, in collaboration with Professor Kim Baek of Mori University, USA, is conducting research to establish the STP03-0404 mechanism of action. Through this mission, the team will receive approximately $ 1.39 million from the NIH for five years.

Earlier this year, Esti Pharm collaborated with Kim Bong-Jin and Son Jong-Chan of the Korea Institute for Chemical Technology Research. STP03-0404. In September 2016, we received a technology transfer from the Korean Institute for Chemical Technology Research.·The company has obtained patent rights and exclusive development rights for the next year.

According to NIH data, an estimated 36 million HIV patients are infected by 2016. On average, about 5,000 new infections occur each day.

"AIDS has been clbadified as a chronic disease, not a deadly disease, but it is still urgent to develop a therapeutic drug because of the development of tolerance," said a STEFILM official. "With the development of HIV treatment for 30 years," We hope that collaborative research will play an important role in the development of treatments for HIV infections. "" We will do our best to succeed in development new medicines for HIV-infected patients, "he added.

Park Hye-jung reporter [email protected]